Tuesday, September 22, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 11, 2026

Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge?

View original at finance.yahoo.com
“For AstraZeneca, the latest twelve month Free Cash Flow (FCF) is about US$9.49b.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AstraZeneca has a valuation score of 3 out of 6

    60% confidence

  • AstraZeneca's DCF analysis suggests the stock is undervalued by 36.2%

    60% confidence

  • The DCF model arrives at an estimated intrinsic value of US$238.68 per share for AstraZeneca

    60% confidence

Data points we hold from this source

AstraZeneca AB · stock return 30day5.2 percent
AstraZeneca AB · stock return 1year54.8 percent
AstraZeneca AB · free cash flow9.49 USD
AstraZeneca AB · stock return ytd12.1 percent
AstraZeneca AB · projected free cash flow20.16 USD
AstraZeneca AB · valuation score3 out_of_6
AstraZeneca AB · intrinsic value dcf238.68 USD
AstraZeneca AB · stock return 7day-0.6 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com
Is It Too Late To Consider AstraZeneca (LSE:AZN) After Its 54.8% One-Year Surge? — Source | Via News | Via News